USPTO Patent Grant for Chimeric Antigen and T Cell Receptors

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12583923B2 to Kite Pharma, Inc. for chimeric antigen and T cell receptors and methods of use. The patent covers novel CAR or TCR constructs designed for potential cancer treatment applications.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12583923B2, titled 'Chimeric antigen and T cell receptors and methods of use,' to Kite Pharma, Inc. This patent grants exclusive rights for novel chimeric antigen receptor (CAR) or T cell receptor (TCR) constructs that include antigen binding motifs, specifically mentioning binding to CD20 and optionally CD19. The patent also covers polynucleotides encoding these receptors and methods of their production and use, particularly in the treatment of cancer.

While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it signifies intellectual property protection for specific biotechnological innovations. Companies operating in the oncology and cell therapy space, particularly those developing CAR-T therapies targeting CD20 and CD19, should be aware of this granted patent. It may impact their freedom to operate, research and development strategies, and potential licensing or collaboration opportunities. No immediate compliance actions are required, but legal and R&D teams should review the patent's claims to understand the scope of protection and potential implications for their product pipelines.

Source document (simplified)

← USPTO Patent Grants

Chimeric antigen and T cell receptors and methods of use

Grant US12583923B2 Kind: B2 Mar 24, 2026

Assignee

Kite Pharma, Inc.

Inventors

Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius

Abstract

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

CPC Classifications

A61K 39/3955 A61K 39/39558 A61K 40/11 A61K 40/31 A61K 40/32 A61K 40/33 A61K 40/4211 A61K 40/421 A61K 40/4224 C07K 16/2896 C07K 16/2803 C07K 16/2887 C12N 5/0636 C12N 5/10 C12N 15/63